NNovartis Read More Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners2026-09-28 On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent…
NNovartis Read More Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial2026-09-14 Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial Proactive uses images sourced from Shutterstock Novartis…
NNovartis Read More Novartis’ Del-desiran Fails Late-Stage DM1 Study, Shares Fall2026-09-09 Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type…
NNovartis Read More Novartis DM1 Drug Misses Primary Endpoint in Phase III Trial2026-09-08 Medical research testing sample ©StockMix Novartis (NYSE:NVS) said on Tuesday that its experimental treatment for myotonic dystrophy type…
NNovartis Read More Novartis’ Rhapsido Meets Primary Goal in Phase III Skin Disorder Study2026-06-20 Novartis NVS announced positive results from the RemIND study on Rhapsido (remibrutinib) for chronic inducible urticaria (CIndU), a…
NNovartis Read More Novartis’ Rhapsido Meets Primary Goal in Phase III Skin Disorder Study2026-06-15 Novartis NVS announced positive results from the RemIND study on Rhapsido (remibrutinib) for chronic inducible urticaria (CIndU), a…
RRoche Read More Roche’s prasinezumab shows promise on PD progression with five-year data2026-03-24 At the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Roche showcased new…
RRoche Read More Roche and Zealand’s Phase II obesity trial divides analyst opinion2026-03-09 Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial,…
RRoche Read More Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease2026-02-18 F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
RRoche Read More Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)2026-02-17 F. Hoffmann-La Roche Ltd Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary…
RRoche Read More Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease2026-02-16 F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
RRoche Read More Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease2026-02-16 F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…